Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?

Oliver, 2021, MMWR Morb Mortal Wkly Rep, 69, 1653, 10.15585/mmwr.mm695152e1

Mahase, 2021, BMJ, 372, n74, 10.1136/bmj.n74

Mahase, 2020, BMJ, 371, m4714, 10.1136/bmj.m4714

Mahase, 2020, BMJ, 370, m3205, 10.1136/bmj.m3205

Voysey, 2021, Lancet, 397, 881, 10.1016/S0140-6736(21)00432-3

Stephenson, 2021, JAMA

Galloway, 2021, MMWR Morb Mortal Wkly Rep, 70, 95, 10.15585/mmwr.mm7003e2

Tegally, 2020, medRxiv

Wrapp, 2020, Science, 367, 1260, 10.1126/science.abb2507

Duan, 2020, Front Immunol, 11, 576622, 10.3389/fimmu.2020.576622

Rui, 2021, Int J Environ Res Public Health, 18, 774, 10.3390/ijerph18020774

Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the spike protein. Updated 2020. Accessed March 19, 2021. https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585

GISAID. UK reports new variant, termed VUI 202012/01. Updated 2020. Accessed March 19, 2021. https://www.gisaid.org/references/gisaid-in-the-news/uk-reports-new-variant-termed-vui-20201201/

Teruel, 2020, bioRxiv

Rathnasinghe, 2021, medRxiv

Koyama, 2020, Pathogens, 9, 324, 10.3390/pathogens9050324

Weissman, 2021, Cell Host Microbe, 29, 23, 10.1016/j.chom.2020.11.012

Zhang, 2020, Nat Commun, 11, 6013, 10.1038/s41467-020-19808-4

Chen, 2020, J Mol Biol, 432, 5212, 10.1016/j.jmb.2020.07.009

Gaebler, 2021, Nature, 591, 639, 10.1038/s41586-021-03207-w

Greaney, 2021, Cell Host Microbe, 29, 463, 10.1016/j.chom.2021.02.003

Andreano, 2020, bioRxiv

Wu, 2021, bioRxiv

Wang, 2021, Nature

Sapkal, 2021, bioRxiv

Emary, 2021, Lancet, 397, 1351, 10.1016/S0140-6736(21)00628-0

van der Lubbe, 2021, NPJ Vaccines, 6, 39, 10.1038/s41541-021-00301-y

Novavax. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial. Updated 2021. Accessed January 28, 2021. https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3

Liu, 2021, Cell Host Microbe, 29, 477, 10.1016/j.chom.2021.01.014

Pujhari, 2020, Virulence, 11, 486, 10.1080/21505594.2020.1763637

Hansen, 2020, Science, 369, 1010, 10.1126/science.abd0827

Environmental and Modelling Group (EMG) and New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG). SARS-COV-2: transmission routes and environments, 22 October 2020. Updated 2020. Accessed March 19, 2021. https://www.gov.uk/government/publications/sars-cov-2-transmission-routes-and-environments-22-october-2020